Kabita Nanda
A5104077848- Autoimmune and Inflammatory Disorders Research
- Adolescent and Pediatric Healthcare
- Vasculitis and related conditions
- Heme Oxygenase-1 and Carbon Monoxide
- Acute Lymphoblastic Leukemia research
- Inflammasome and immune disorders
- Kawasaki Disease and Coronary Complications
- Systemic Lupus Erythematosus Research
- Renal Diseases and Glomerulopathies
- Immunodeficiency and Autoimmune Disorders
- Inflammatory Myopathies and Dermatomyositis
- Retinal and Optic Conditions
- Muscle and Compartmental Disorders
- Neonatal Health and Biochemistry
- Homelessness and Social Issues
- Innovations in Medical Education
- Ocular Diseases and Behçet’s Syndrome
- Thermal Regulation in Medicine
- Digital Mental Health Interventions
- Complement system in diseases
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Hate Speech and Cyberbullying Detection
- Clinical Reasoning and Diagnostic Skills
- Cloud Data Security Solutions
- Hereditary Neurological Disorders
Seattle Children's Hospital
2013-2024
University of Washington
2015-2024
Sri Siddhartha Medical College
2016-2024
Siddaganga Institute of Technology
2016
Comer Children's Hospital
2014
Seattle University
2014
Rainbow Babies & Children's Hospital
2012-2014
Objective To uniquely classify children with microscopic polyangiitis (MPA), to describe their demographic characteristics, presenting clinical features, and initial treatments in comparison patients granulomatosis (Wegener's) (GPA). Methods The European Medicines Agency (EMA) classification algorithm was applied by computation categorical data from recruited the ARChiVe (A Registry for Childhood Vasculitis: e‐entry) cohort, censored November 2015. EMA used distinguish MPA GPA, whose...
Abstract Objective To investigate the safety and efficacy of subcutaneous tocilizumab (SC-TCZ) treatment in a long-term extension (LTE) clinical trials polyarticular or systemic juvenile idiopathic arthritis (pJIA sJIA). Methods Patients with pJIA sJIA from two open-label, 52-week phase 1b core SC-TCZ who had adequate response per investigator assessment entered LTE continued according to body weight–based dosing regimens until commercial availability up 5 years. Pharmacokinetics,...
To determine s.c. tocilizumab (s.c.-TCZ) dosing regimens for systemic JIA (sJIA) and polyarticular (pJIA).In two 52-week phase 1 b trials, s.c.-TCZ (162 mg/dose) was administered to sJIA patients every week or 2 weeks (every 10 days before interim analysis) pJIA 3 with body weight ≥30 kg <30 kg, respectively. Primary end points were pharmacokinetics, pharmacodynamics safety; efficacy exploratory. Comparisons made data from trials i.v. (i.v.-TCZ) in pJIA.Study participants 51 52 aged 1-17...
This study aimed to assess long-term safety and developmental data on juvenile idiopathic arthritis (JIA) patients treated in routine clinical practice with celecoxib or nonselective nonsteroidal anti-inflammatory drugs (nsNSAIDs). Children aged ≥2 <18 years rheumatoid-factor–positive –negative polyarthritis, persistent extended oligoarthritis, systemic were enrolled into this prospective, observational, multicenter standard-of-care registry. Eligible newly recently prescribed (≤6 months) an...
Abstract Background Juvenile idiopathic arthritis (JIA)-associated uveitis is a chronic paediatric ocular inflammatory condition that can result in visual impairment. Adalimumab, tumour necrosis factor (TNF)-alpha inhibitor, effectively controls joint and eye inflammation; however, its long-term use may increase the risk of adverse health outcomes place an undue financial burden on patient healthcare system given high cost. There great interest for patients to stop adalimumab following...
To evaluate safety and effectiveness of adalimumab (ADA) in polyarticular-course juvenile idiopathic arthritis (JIA) the STRIVE registry.STRIVE enrolled patients with JIA into 2 arms based on treatment methotrexate (MTX) alone or ADA with/without MTX (ADA ± MTX). Adverse events (AEs) per 100 patient-years observation time were analyzed by registry arm. Patients who entered within 4 weeks starting MTX, defined as new users, evaluated for change disease activity assessed 27-joint Juvenile...
Abstract Background Heme oxygenase-1 (HMOX1) catalyzes the metabolism of heme into carbon monoxide, ferrous iron, and biliverdin. Through biliverdin reductase, becomes bilirubin. HMOX1 -deficiency is a rare autosomal recessive disorder with hallmark features direct antibody negative hemolytic anemia normal bilirubin, hyperinflammation similar to macrophage activation syndrome. Clinical findings have included asplenia, nephritis, hepatitis, vasculitis. Pulmonary evaluation immune response...
Objective. There are no validated tools for measuring disease activity in pediatric vasculitis. The Birmingham Vasculitis Activity Score (BVAS) is a valid tool adult Version 3 (BVAS v.3) correlates well with physician’s global assessment (PGA), treatment decision, and C-reactive protein adults. utility of BVAS v.3 vasculitis not known. We assessed the association scores PGA, erythrocyte sedimentation rate (ESR) at diagnosis antineutrophil cytoplasmic antibody-associated (AAV). Methods....
Objective We examine levels of candidate blood‐based biomarkers (CBBs) in patients with juvenile idiopathic arthritis (JIA) treated tofacitinib. Methods Patients JIA who participated clinical trial NCT02592434 received tofacitinib from baseline to week 18. Serial serum samples were assayed for CBBs (S100A8/9, S100A12, interleukin‐18 [IL‐18], amyloid A, resistin, vascular endothelial growth factor, angiopoietin‐1, angiopoietin‐2, matrix metalloproteinase 8 [MMP8], MMP2, tissue inhibitor...
We describe a Childhood Arthritis and Rheumatology Research Alliance (CARRA) survey of North American pediatric rheumatologists that assesses physician attitudes on withdrawal medications in systemic juvenile idiopathic arthritis (SJIA). A REDCap anonymous electronic was distributed to 100 random CARRA JIA workgroup physician-voting members. The had three broad sections including: A) demographic information; B) physicians' opinions clinical inactive disease (CID) SJIA C) existing practices...
Few data are available regarding the rates of serious adverse events (SAEs) and important medical (IMEs) outside product-based registries clinical trials for juvenile idiopathic arthritis (JIA). The Enhanced Drug Safety Surveillance Project (EDSSP) was developed to pilot a novel system collect SAEs/IMEs in children with JIA. This analysis reports results from this 4-year (2008-2012) EDSSP.Participating physicians were surveyed monthly ascertain whether their JIA patients experienced an SAE...
Abstract Tumor necrosis factor α ( TNF ‐α) antagonists are used in the treatment of numerous autoimmune conditions. Adalimumab is first monoclonal antibody to ‐α and treat juvenile idiopathic arthritis. A growing body literature associates anti‐ therapies with several adverse dermatologic manifestations, including drug‐induced lupus erythematosus (LE). We describe a case cutaneous LE 16‐year‐old girl treated adalimumab for The temporal association between her presenting symptoms initiation...
Cloud computing aims at allowing access to large amount of power in a fully virtualized manner, by aggregating resources and offering single system view. More more businesses individuals are attracted the benefits cloud shifting their data computation work be carried out cloud. But since processing users is done remote placed storage systems, has fear about security data. These distributed nature. To address this issue we utilizing framework called Information Accountability. This uses...
Background/Purpose: Comparisons of pediatric ANCA-associated vasculitis subtypes (AAV) are limited by the paucity reported cases, standardized definitions, and overlapping classification criteria. Published work from ARChiVe (A Registry for Childhood Vasculitis) demonstrated modifications validated algorithms applied to patients with AAV can classify each patient mutually exclusive diagnostic categories. We compared presenting features children microscopic polyangiitis (MPA)...
Abstract Objectives Four-and-a-half LIM domains 1 (FHL1) is a muscle-specific protein. Autoantibodies against FHL1 were recently discovered in adults with idiopathic inflammatory myopathies (IIMs) and found to be associated clinical features outcomes indicative of increased disease severity. Anti-FHL1 autoantibodies have not been described children. Here, the prevalence anti-FHL1 examined large North American cohort juvenile patients IIM. Methods Sera from 338 IIM 91 healthy controls...
Abstract Background Childhood-onset Systemic Lupus Erythematosus (cSLE) is an autoimmune disease associated with fatigue, mood symptoms, and pain. Fortunately, these symptoms are potentially modifiable psychological intervention such as cognitive-behavioral therapy (CBT). The Treatment Education Approach for (TEACH) program a CBT developed to target adolescents young adults cSLE. This pilot randomized controlled trial (RCT) aims determine the feasibility effect of TEACH youth Adjustments...
Juvenile dermatomyositis (JDM) is a multisystem vasculopathy that infrequently presents with acute complications. We report here case of 12-year-old girl Dermatomyositis who developed Thrombotic Thrombocytopenic purpura (TTP) and Purtscher's retinopathy. The diagnosis JDM was based on her clinical presentation (fever, myalgia, proximal muscle weakness, characteristic skin rash elevated enzymes). Despite improvement rash, fever weakness corticosteroids intravenous Immunoglobulins (IVIG), the...
Chronic anterior uveitis (CAU) carries a significant risk for eye complications and vision loss. The Childhood Arthritis Rheumatology Research Alliance (CARRA) introduced consensus treatment plans (CTPs) to standardize CAU facilitate future comparative effectiveness studies. Two CTPs were developed address: 1) initiation of methotrexate (MTX) in patients with naïve steroid-sparing therapy, 2) TNF inhibitor (TNFi) severe or refractory MTX. We evaluated implementation the using existing CARRA...
Methods Here we describe a previously healthy and athletic 12 year old female who was diagnosed with JDM following period of two weeks pruritic rash, fever, headaches, muscle pain weakness. Her work-up significant for elevated enzymes an abnormal MRI bilateral quadriceps that demonstrated increased signal intensity. The patient hospitalized intravenous pulse methylprednisolone immunoglobulin (IVIG) treatment. She showed improvement in her skin rash weakness, discharged oral prednisone,...